PDS BIOTECHNOLOGY CORP

PDS Biotechnology Corporation is a clinical-stage biotechnology company whose core product development relies on animal testing. Its lead investigational cancer immunotherapy, PDS0101, has progressed through preclinical studies involving animal models, a standard practice in the pharmaceutical industry to assess safety and efficacy before human trials. The company’s research and development activities inherently involve the commercial exploitation of animals for biomedical testing.

The specific welfare impacts of such testing are documented in industry studies. For example, a 2020 toxicity study on an investigational compound, conducted in cynomolgus monkeys, references adherence to animal welfare decrees, highlighting the procedural scale involved. While PDS Biotechnology itself has not been cited for direct Animal Welfare Act violations, the broader biopharmaceutical sector it operates within has faced significant penalties for non-compliance, including a landmark $3.5 million settlement by a research facility in 2016 for animal welfare violations. This underscores the systemic animal exploitation risk inherent to the company's business model.